Epidemiological profile and clinical outcomes of very young (<35 years) and young (35-50 years) patients with STEMI: Insights from the NORIN STEMI registry.

BACKGROUND: Despite significant progress in primary prevention, rates of myocardial infarction (MI) in South Asian population is alarmingly high. OBJECTIVES: We sought to compare risk factor profiles and outcomes between individuals with ST-Segment Elevation Myocardial Infarction (STEMI) in young (<50 years) and old (≥50 years) age groups. METHODS: North India STEMI Registry (NORIN-STEMI) is a prospective observational registry of patients hospitalised with STEMI. We conducted a study of young patients (<50 years) regarding their risk factors for coronary artery disease (CAD), in-hospital and 30-day mortality and compared with their older counterpart. RESULTS: Among 5335 patients enrolled, 1752 (32.8%) were young and were 19 years younger than the older cohort. Major risk factors in young patients were physical inactivity (75.1%) and alcohol intake (67.8%). Higher prevalence of tobacco use (66.6% vs 52.4%), but lower prevalence of diabetes (16% vs 26.3%) and hypertension (18.5% vs 29.9%) were seen in young STEMI. Young patients were less likely to die both in-hospital (5.9% vs 10.0%) and at 30-days (11.1% vs 16.2%). Left ventricular ejection fraction (LVEF) < 30% at admission [OR: 8.00, 95% confidence interval (CI): 4.60-13.90, P < 0.001 in-hospital, OR: 3.92, 95% CI: 2.69-5.73 at 30-days] and female sex were strongest predictors of mortality. CONCLUSIONS: Young STEMI patients constituted one-third of total cohort. Most of them were tobacco consumers with lesser prevalence of diabetes and hypertension. They were less likely to die both in-hospital and at 30 days because of earlier presentation to a health care facility and hence a relatively preserved LVEF.

Comparison of different cardiovascular risk score calculators for cardiovascular risk prediction and guideline recommended statin uses.

OBJECTIVE: The accuracy of various 10-year cardiovascular disease (CVD) risk calculators in Indians may not be the same as in other populations. Present study was conducted to compare the various calculators for CVD risk assessment and statin eligibility according to different guidelines. METHODS: Consecutive 1110 patients who presented after their first myocardial infarction were included. Their CVD risk was calculated using Framingham Risk score- Coronary heart disease (FRS-CHD), Framingham Risk Score- Cardiovascular Disease (FRS-CVD), QRISK2, Joint British Society risk calculator 3 (JBS3), American College of Cardiology/American Heart Association (ACC/AHA), atherosclerotic cardiovascular disease (ASCVD) and WHO risk charts, assuming that they had presented one day before cardiac event for risk assessment. Eligibility for statin uses was also looked into using ACC/AHA, NICE and Canadian guidelines. RESULTS: FRS-CVD risk assessment model has performed the best as it could identify the highest number of patients (51.9%) to be at high CVD risk while WHO and ASCVD calculators have performed the worst (only 16.2% and 28.3% patients respectively were stratified into high CVD risk) considering 20% as cut off for high risk definition. QRISK2, JBS3 and FRS-CHD have performed intermediately. Using NICE, ACC/AHA and Canadian guidelines; 76%, 69% and 44.6% patients respectively were found to be eligible for statin use. CONCLUSION: FRS-CVD appears to be the most useful for CVD risk assessment in Indians, but the difference may be because FRS-CVD estimates risk for several additional outcomes as compared with other risk scores. For statin eligibility, however, NICE guideline use is the most appropriate.

Abnormal glycemic profiles by CGMS in obese first-degree relatives of type 2 diabetes mellitus patients.

INTRODUCTION: The conventionally used oral glucose tolerance test (OGTT) has been the mainstay for diagnosis of diabetes and prediabetes. However, recent studies have indicated that a continuous glucose monitoring system (CGMS) could detect impaired glycemia much earlier than OGTT, especially in certain groups. We aimed to study the 24-h glucose profile of high-risk obese first-degree relatives of type 2 diabetes patients by CGMS and ascertain if it was better than OGTT for early detection of type 2 diabetes. SUBJECTS AND METHODS: CGMS data of 20 subjects each in normal glucose tolerance (NGT), impaired fasting glucose (IFG), impaired glucose tolerance (IGT), and newly detected diabetes mellitus (NDDM) groups were obtained. We considered minimum, maximum, mean, and range of glucose levels as well as number, duration, and area under the curve (AUC) for excursions. RESULTS: We found three (15%) NGT, seven (35%) IFG, and eight (40%) IGT subjects showed excursions in the diabetes range, whereas 18 (90%) NGT and 17 (85%) pure IFG subjects showed excursions in the IGT range. The maximum glucose values for NGT and IFG subjects were 176.0±41.4 mg/dL and 186.5±39.3 mg/dL, respectively, which is much above the present 2-h OGTT cutoff limit of 140 mg/dL. However, the average number of excursions and AUC of excursions did not differ significantly among the NGT, IFG, and IGT groups. The differences in the duration of excursion between NGT subjects with IFG values and NGT subjects with IGT values were statistically significant for an excursion limit of 140 mg/dL. However, this did not differ significantly between the IFG and IGT groups. CONCLUSIONS: CGMS indicated the presence of significant dysglycemia in first-degree relatives of diabetes patients without diabetes who were centrally obese. Hence it could be useful for early identification of individuals at greater risk of diabetes. A deranged glycemic profile may precede onset of overt diabetes by a long time, which may partly explain why some patients with new-onset type 2 diabetes or even prediabetes present with vascular complications at the outset.